Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Royalty Pharma plc Class A Ordinary Shares

RPRX

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Last trade $68.27
Day change -$0.255 (-0.37%)
Day range $67.77 – $70.35
Volume 1,341,168
Market cap $30.51B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$30.51B
Price / earnings
45.44×
Price / book
4.46×
Price / sales
11.66×
EV / sales
14.75×
EV / EBITDA
22.08×

Profitability

Earnings per share
$1.51
Return on assets
3.45%
Return on equity
9.82%
Dividend yield
1.34%

Liquidity and leverage

Debt / equity
1.26×
Current ratio
1.29×
Quick ratio
1.29×
Cash ratio
0.44×

Cash flow

Price / cash flow
10.31×
Price / free cash flow
10.31×
Free cash flow
$2.96B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RPRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$690.1M$674.14M$630.58M$621.99M$609.29M$578.67M$568.25M$593.64M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$690.1M$674.14M$630.58M$621.99M$609.29M$578.67M$568.25M$593.64M
Selling, general and administrative$150.1M$161.89M$159.49M$164.27M$118.73M$179.77M$110.71M$67.59M
Research and development$63.16M$97.85M$39.79M$50.5M$50.5M$300.5M$50.5M$500K
Total operating expenses$279.27M$541.02M$67.54M$233.61M$182.14M$368.87M$34.07M$232.13M
Operating income$410.84M$133.12M$563.04M$388.38M$427.16M$209.8M$534.18M$361.51M
Interest expense-$90.49M-$93.62M-$93.72M-$94.17M-$79.56M-$68.67M-$65.26M-$65.76M
Income before taxes$266.64M$81.49M$468.26M$355.91M$440.21M$92.64M$434.43M$334.35M
Income taxes$0$0$0$0$0$0$0$0
Net income$266.64M$81.49M$468.26M$355.91M$440.21M$92.64M$434.43M$334.35M
Net income attributable to common shareholders$144.68M$17.88M$294.69M$214.21M$284.22M$32.18M$239.35M$208.21M
EBITDA$472.88M$133.12M$435M$707.33M$439.29M$209.8M$407.04M-$206.91M
Basic earnings per share$0.32$0.04$0.67$0.50$0.66$0.08$0.55$0.47
Diluted earnings per share$0.32$0.04$0.67$0.38$0.66$0.07$0.55$0.35

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug

Revolution Medicines' pancreatic cancer drug daraxonrasib received FDA approval and could generate peak revenues of $11 billion. Royalty Pharma, which financed the drug, stands to earn up to $340 million in peak royalties without doing the development work. While Revolution Medicines stock has surged 200% in the past year, Royalty Pharma offers a more diversified alternative with investments in 35 approved drugs and a 1.4% dividend yield.

Zacks Investment Research

Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?

Royalty Pharma (RPRX) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improving business fundamentals and positive earnings estimate revisions.

Zacks Investment Research

RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake

Revolution Medicines reported Q3 2026 results with a narrower-than-expected loss of $1.90 per share and revenues of $197.6 million, entirely from Rasonque sales following its FDA approval in late August. The drug reached over 5,000 patients in five weeks with strong reimbursement coverage. The company maintained its 2026 operating expense guidance and holds a strong cash position of $3.7 billion. European approval is pending, and multiple late-stage studies are underway for pancreatic cancer and other RAS-mutant cancers.

The Motley Fool

Should You Buy Royalty Pharma Stock Before Nov. 4?

Royalty Pharma shares have rallied toward 52-week highs ahead of Q3 2026 earnings on Nov. 4, but investors should focus on long-term prospects rather than short-term earnings catalysts. Analysts expect 8.7% sales growth and flat earnings, with potential upside from positive pipeline updates on cancer treatments and other drug candidates, though negative news on pelacarsen could weigh on the stock.

Zacks Investment Research

Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Guardant Health is expected to report Q3 2026 earnings on November 5 with a consensus loss of $0.29 per share and revenues of $350.83 million (up 32.3% YoY). The company has a positive Earnings ESP of +4.76% combined with a Zacks Rank #3, suggesting it will likely beat consensus estimates. However, recent estimate revisions have been 6.86% lower over the last 30 days.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Nov 13, 2026$0.235Dec 10, 2026recurring
Aug 14, 2026$0.235Sep 10, 2026recurring
May 15, 2026$0.235Jun 10, 2026recurring
Feb 20, 2026$0.235Mar 10, 2026recurring
Nov 14, 2025$0.22Dec 10, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 15, 20101-for-4reverse split